PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW145468View Pathway |
drug action
Lopinavir Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:53 Last Updated: October 07, 2023 at 15:53 |
PW144572View Pathway |
drug action
Loracarbef Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:55 Last Updated: October 07, 2023 at 13:55 |
PW176083View Pathway |
Loracarbef Predicted Metabolism Pathway newHomo sapiens
Metabolites of Loracarbef are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 13:49 Last Updated: November 29, 2023 at 13:49 |
PW144579View Pathway |
drug action
Loratadine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:56 Last Updated: October 07, 2023 at 13:56 |
PW176624View Pathway |
drug action
Loratadine H1 Antihistamine Smooth Muscle Relaxation Action PathwayHomo sapiens
Loratadine is a long-acting, second-generation, non-sedating tricyclic antihistamine (piperidine derivative) with selective antagonistic properties to peripheral histamine H1-receptors. Loratadine selectively inhibits H1-receptors primarily located on respiratory smooth muscle cells, vascular endothelial cells, the gastrointestinal tract, and immune cells. Unlike the first-generation antihistamines such as diphenhydramine, loratadine is a competitive histamine antagonist that does not cross the blood-brain barrier. Therefore, it does not affect the neurons of the central nervous system, thereby preventing daytime somnolence or sedation. Loratadine binds to H1-receptors in different cells and causes a decrease in vascular permeability (prevents edema and flushing), decreases smooth muscle tone (bronchodilation), and decreases the activation of the peripheral nociceptive receptors (decreases pain and pruritus). At high concentrations, second-generation antihistamines such as loratadine can inhibit histamine release from mast cells and basophils, thereby reducing ICAM-1 expression in epithelial cells and inhibiting type 1 hypersensitivity reactions (e.g., hay fever, urticaria, pruritus, edema).
|
Creator: Ray Kruger Created On: December 19, 2023 at 12:59 Last Updated: December 19, 2023 at 12:59 |
PW061144View Pathway |
drug action
Loratadine H1-Antihistamine ActionHomo sapiens
Loratadine is a second-generation tricyclic H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.
|
Creator: Carin Li Created On: September 19, 2017 at 22:24 Last Updated: September 19, 2017 at 22:24 |
PW126586View Pathway |
drug action
Lorazepam Action PathwayHomo sapiens
Lorazepam is a short-acting benzodiazepine commonly used for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.
Lorazepam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane.
According to the binding site of lorazepam, we can observe different activities as the binding in the amygdala is known to help mainly in anxiety disorders while the binding in the cerebral cortex helps in seizure disorders.
|
Creator: Karxena Harford Created On: January 18, 2022 at 23:02 Last Updated: January 18, 2022 at 23:02 |
PW144317View Pathway |
drug action
Lorazepam Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 13:23 Last Updated: October 07, 2023 at 13:23 |
PW145604View Pathway |
drug action
Lorcaserin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:11 Last Updated: October 07, 2023 at 16:11 |
PW146497View Pathway |
drug action
Lorlatinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:20 Last Updated: October 07, 2023 at 18:20 |